Two separate clinical trials were performed by Dr. Anthony Bella, one of the top 5 urological surgeons in the world. The trials showed Xialla to be effective in treating moderate to severe ED when used alone and in combination with drug or injection therapy.
Dr. Bella was named a Fellow of the Royal College of Surgeons, Canada (Urology) and then completed a combined research and clinical fellowship in Neurourology and Erectile Dysfunction at the University of California San Francisco. In 2007, Dr. Bella returned to Canada, and in addition to his clinical and surgical responsibilities, was named Associate Scientist, Neuroscience at the OHRI, University of Ottawa, maintaining an active neuroscience laboratory through 2013.
Dr. Bella has coauthored more than 100 peer-reviewed publications, including chairing the 2015 Canadian Urological Association Guidelines, and multiple book chapters in the medical literature focusing on both clinical care and de novo research. Dr. Bella has widely consulted for the pharmaceutical industry over the past decade, and has held advisory positions for Eli Lilly, Pfizer, Bayer, Abbott, and Endo Pharmaceuticals/ American Medical Systems. Dr. Bella is a member of the Canadian Urological Association, American Urological Association, International Society for Sexual Medicine, Sexual Medicine Society of North America, and currently holds medical and surgical licensure in Canada and California.
Xialla is a new FDA and Health Canada compliant medical device consisting of a soft silicone occlusion loop (SSOL) with geodesigned anchoring. The SSOL design is novel, offering a unique means of loop fixing compared to traditional penile occlusion bands (POB) or c*ck rings (CR).
The current version of Xialla represents V2 of the device and is a significant enhancement in several ways; easier to wear, less obvious visually, more comfortable, less prone to deflection of fixation due to inner thigh fat pads.
We identified complimentary force vectors to circular constriction applied by the anchoring mechanism and theorized that this may optimize venous trapping in CVOD ED.
Finally, the design of the SSOL is less obtrusive to the man and his partner, and does not impact external genitalia of the partner, which may make acceptance as a sexual function (SF) enhancement device for intimacy easier.